Investor Relations

Overview

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections. Our lead product candidate, lefamulin, is being developed as the first pleuromutilin antibiotic for intravenous (IV) and oral administration in humans. We reported positive topline efficacy and favorable tolerability results from the LEAP 1 and LEAP 2 pivotal Phase 3 trials for the treatment of community-acquired bacterial pneumonia (CABP) in adults. We believe lefamulin has the potential to be developed for additional uses and we are working to build a robust pipeline of products. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

SEC Filings

Filing date Description Form Filing Group View

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

Investor Contacts

David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc
E-mail: david.garrett@nabriva.com